Trial Profile
Virologic Outcomes of Changing Enfuvirtide to Raltegravir in HIV-1 Patients Well Controlled on an Enfuvirtide Based Regimen.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms CHEER
- 07 Jun 2011 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 07 Jun 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Oct 2009 Planned end date (Jun 2008) added as reported by ClinicalTrials.gov.